Results 31 to 40 of about 49,935 (237)

Real-World Comparative Effectiveness of Tofacitinib and Tumor Necrosis Factor Inhibitors as Monotherapy and Combination Therapy for Treatment of Rheumatoid Arthritis

Rheumatology and Therapy, 2019
Introduction No published studies exist comparing the effectiveness of tofacitinib with other advanced therapies for the treatment of rheumatoid arthritis (RA) in real-world clinical practice.
George W. Reed, Robert A. Gerber, Ying Shan, Liza Takiya, Kimberly J. Dandreo, David Gruben, Joel Kremer, Gene Wallenstein   +7 more
doaj   +1 more source

Tofacitinib in Patients With Psoriatic Arthritis and Metabolic Syndrome: A Post hoc Analysis of Phase 3 Studies

ACR Open Rheumatology, 2020
Objective Metabolic syndrome (MetS) is a cluster of concurrent risk factors for cardiovascular disease and type 2 diabetes. This post hoc analysis explored key efficacy and safety endpoints in patients with psoriatic arthritis (PsA) and MetS treated with
Christopher T. Ritchlin, Jon T. Giles, Alexis Ogdie, Juan J. Gomez‐Reino, Philip Helliwell, Pamela Young, Cunshan Wang, Joseph Wu, Ana Belén Romero, John Woolcott, Lori Stockert   +10 more
doaj   +1 more source

Efficacy and safety of tofacitinib by background methotrexate dose in psoriatic arthritis: post hoc exploratory analysis from two phase III trials.

, 2021
OBJECTIVE: Analyze tofacitinib efficacy and safety by background methotrexate (MTX) dose in patients with psoriatic arthritis (PsA). METHODS: This post hoc analysis pooled data from two phase III, double-blind trials (OPAL Broaden, NCT01877668; OPAL ...
Azevedo, Valderilio F, Pang, Shirley, Takiya, Liza, Wang, Cunshan, Kivitz, Alan J, FitzGerald, Oliver, Nash, Peter   +6 more
core   +1 more source

Analysis of Tofacitinib and Baricitinib as Second and third Line treatment in theumatoid arthritis: systematic review of cost effectiveness studies

, 2021
Introducción: La Artritis Reumatoide una enfermedad crónica, con daño irreversible, es importante conocer los costos asociados a su tratamiento, el cual tiene como objeto llevar al paciente a un estado de remisión.
Betancur Romero, John Edison, Carrasco Muñoz, Paola Andrea   +1 more
core   +1 more source

Tofacitinib Use in Adults with Chronic Inflammatory Disease During the Severe Acute Respiratory Syndrome Coronavirus 2 Pandemic: What Is Known So Far?

Current Therapeutic Research, 2021
: Background: Concerns have been raised that the risk of severe acute respiratory syndrome coronavirus 2 infection, or more severe or critical coronavirus disease 2019 (COVID-19), may be higher in immunocompromised individuals receiving immunomodulatory
Samantha Howland, MPharm, J. Jasper Deuring, PhD, Xiaofeng Zhou, PhD, Yan Chen, MD, PhD, Licia MH Mota, MD, Ryan C. Ungaro, MD, MS   +5 more
doaj   +1 more source

Time to improvement of pain, morning stiffness, fatigue, and disease activity in patients with ankylosing spondylitis treated with tofacitinib: a post hoc analysis

Arthritis Research & Therapy
Background Tofacitinib is an oral Janus kinase inhibitor for treatment of ankylosing spondylitis (AS). Time to improvement in core domains of AS was estimated in tofacitinib-treated patients with AS. Methods This post hoc analysis used phase 3 trial data
Victoria Navarro-Compán, Atul Deodhar, Rachid Bahiri, Andrew G. Bushmakin, Joseph C. Cappelleri, Jihane Rammaoui   +5 more
doaj   +1 more source

DECODE: Knowledge, Attitude, and Practices of Indian Dermatologists on the Scope of Tofacitinib in Dermatological Disorders

Clinical Dermatology Review
Background: Given the evolving treatment landscape in clinical dermatology, understanding the efficacy, safety, and optimal use of tofacitinib for dermatological disorders is crucial.
Pradyumna Vaidya, Ajay Kedia, Rajeev Sekhri, Abir Saraswat, S Kiran, Aseem Sharma   +5 more
doaj   +1 more source

Persistence of Tofacitinib in the Treatment of Rheumatoid Arthritis in Open‐Label, Long‐Term Extension Studies up to 9.5 Years

ACR Open Rheumatology, 2019
Objective Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). This post hoc analysis evaluated tofacitinib persistence in patients with RA in long‐term extension (LTE) studies up to 9.5 years.
Janet E. Pope, Edward Keystone, Shahin Jamal, Lisy Wang, Lara Fallon, John Woolcott, Irina Lazariciu, Douglass Chapman, Boulos Haraoui   +8 more
doaj   +1 more source

Tofacitinib Reduces Spinal Inflammation in Vertebral Bodies and Posterolateral Elements in Ankylosing Spondylitis: Results from a Phase 2 Trial

Rheumatology and Therapy, 2023
Introduction This post hoc analysis of phase 2 trial data assessed the efficacy of tofacitinib on magnetic resonance imaging (MRI) outcomes with the detailed anatomy-based Canada–Denmark (CANDEN) MRI scoring system and evaluated tofacitinib suppression ...
Mikkel Østergaard, Joseph Wu, Lara Fallon, Sarah P. Sherlock, Cunshan Wang, Dona Fleishaker, Keith S. Kanik, Walter P. Maksymowych   +7 more
doaj   +1 more source

Tofacitinib Suppresses Several JAK-STAT Pathways in Rheumatoid Arthritis In Vivo and Baseline Signaling Profile Associates With Treatment Response

Frontiers in Immunology, 2021
ObjectiveCurrent knowledge on the actions of tofacitinib on cytokine signaling pathways in rheumatoid arthritis (RA) is based on in vitro studies. Our study is the first to examine the effects of tofacitinib treatment on Janus kinase (JAK) - signal ...
Maaria Palmroth, Krista Kuuliala, Ritva Peltomaa, Anniina Virtanen, Antti Kuuliala, Antti Kurttila, Anna Kinnunen, Marjatta Leirisalo-Repo, Olli Silvennoinen, Olli Silvennoinen, Olli Silvennoinen, Pia Isomäki, Pia Isomäki   +12 more
doaj   +1 more source